Galera to Present at Piper Sandler Annual Healthcare Conference
November 22, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
November 09, 2022 07:00 ET
|
Galera Therapeutics
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting showed tumor...
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
October 26, 2022 13:40 ET
|
Galera Therapeutics
Tumor outcomes and overall survival maintained in patients with HNC at one-year Cisplatin-related chronic kidney disease reduced by 50% in avasopasem patients compared to placebo at one-year ...
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
September 26, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer
September 01, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
August 09, 2022 07:00 ET
|
Galera Therapeutics
Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual...
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
June 29, 2022 07:30 ET
|
Galera Therapeutics
Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the randomized, double-blinded, placebo-controlled...
Galera to Present at Jefferies Healthcare Conference
June 02, 2022 07:00 ET
|
Galera Therapeutics
MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
May 26, 2022 17:00 ET
|
Galera Therapeutics
Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer receiving radiotherapy Company on...